DUBAI, UAE, Dec. 12, 2023 /PRNewswire/ — The Global Youth Ambassadors of the Global Alliance of Universities on Climate (GAUC) issued a statement today at the 2023 UN Climate Change Conference (COP28), urging global leaders to unite and deliver actions for a prosperous, net-zero, and resilient future.

GAUC representatives at the press conference. From left to right: XIE Zongxu, BAO Rong, Alice HO, Stephen Davison, LI Zheng, ZHENG Yuhan, Rounok Jahan Khan, XIAO Zhihan, Camila Bertranou.

"Youth are the backbone of the net-zero future," said Prof. LI Zheng, the GAUC Secretary-General. To facilitate their transformation from learners of climate knowledge to implementers of climate action, GAUC launched the ‘Climate x’ Campaign. We are proud to see their growth and achievements through the Campaign and would like to continuously work with global multi-stakeholders to prepare them for their historical role as the future leaders in tackling the climate change challenge."

The statement marks the culmination of the journey for the GAUC COP28 Youth Delegation, the flagship project of the ‘Climate x’ Campaign at the international level. Since the beginning of COP28, the GAUC delegation, comprised of 22 delegates from 10 countries, has hosted a GAUC Pavilion in the COP28 Blue Zone, led a GAUC Day in the Blue Zone on December 3rd, organized and spoke on over 100 side-events, and actively engaged in approximately 500 negotiations, side events, and external partnerships.

Alice HO, the GAUC Chief Youth Officer and leader of the GAUC delegation, stated, "With unwavering support from global partners, we are honored to have witnessed and contributed to the global climate governance process. We look forward to a successful closure of COP28 and are well-positioned for more youth-led cooperation and collaborative actions towards a net-zero future"

The ‘Climate x’ Campaign also features a ‘Climate x’ Leadership Training Program, where emerging leaders of the youth delegation have been selected and certified as the 2nd cohort of GAUC Global Youth Ambassadors. Launched in June, the training program has enrolled approximately 1000 students from nearly 400 universities in 78 countries and regions, with over 80% hailing from the Global South. Experts from the member universities of GAUC and its partners have presented around 50 online lectures and workshops.

To convey the climate actions of the younger generation and contribute to a successful COP28, the students are required to hold three events in their local communities, with the third one being organized during the Global Youth Climate Week. Proposed by GAUC to UNFCCC in February, 2022, this international mechanism is scheduled one week prior to each COP. By the opening of COP28, 300 student-led events had been organized, engaging nearly 30,000 people worldwide."

"The training program broadened our knowledge regarding climate change, especially from a synergistic perspective," said Rounok Jahan Khan, a young delegate from Bangladesh. "Such insights have bestowed upon me a deeper engagement at COP28. Our collective journey towards sustainability is not just a story; it’s an unfolding epic."

In addition to the students of the training program, GAUC has also invited members of its 2022 Global Youth Ambassadors to join as Youth Mentors in the delegation. "Our COP28 Youth Delegation has a diverse focus on climate issues, such as critical negotiations on the Global Stocktake, the Global Goal on Adaptation, loss and damage, methane and non-CO2 greenhouse gases, and long-term climate finance," said BAO Rong, a Youth Mentor in the delegation and a graduate of Yale University."  

XIE Zongxu, a youth mentor in the delegation and a Ph.D. candidate from Tsinghua University, emphasized the importance of global collaboration in addressing climate change. "As a youth mentor to the delegation, I am inspired by the passion and dedication of the emerging leaders in the team. Together, we are working towards shared goals of achieving a net-zero future and building resilience against climate impacts. The diversity of perspectives and expertise within our delegation allows us to contribute to a holistic and comprehensive approach to climate action."

Source : Global Youth Issued Statement ahead of the Closing of COP28

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

LOS ANGELES, Dec. 12, 2023 /PRNewswire/ — Former Bachelorette, Charity Lawson, hosted an exquisite tea luncheon with made-to-order evening wear brand, Azazie, in celebration of brides-to-be & their beloved bridal party. Charity was joined by Vanderpump Rules star Charli Burnett, actress Danielle Campbell, and top tier influencers for an afternoon of elegance at the Peninsula Hotel Beverly Hills. Attendees arrived in dazzling dresses from Azazie, offered in sizes 0-30. Check out their stunning looks below!

PHOTOS

Photos Courtesy of Moises Martinez

Bachelorette star Charity Lawson, stepped out in the Azazie Tamara.

Bachelorette star Charity Lawson, stepped out in the Azazie Tamara

Vanderpump Rules star Charli Burnett, looked jaw-droppingly beautiful in the Azazie Bella.

Actress Danielle Campbell styled Azazie’s Scarlette.

ABOUT AZAZIE

Azazie is the leading DTC e-tailer for bridal gowns, bridesmaid dresses, special occasion wear and accessories, Azazie offers direct-to-consumer, high-quality, gowns at affordable prices. Based in the tech capital of Silicon Valley,  Azazie is disrupting the traditional bridal industry while garnering high ratings from customers and review sites alike. With 200+ bridal gowns and 400+ bridal party dresses in over 80 colors,  Azazie is committed to body-positive fashion, offering all dresses from size 0-30, cut and sewn to order like expensive bespoke designs.  Azazie has appeared on The Today Show, CNBC and other top media outlets and won the Glossy Beauty and Fashion Award for the Best E-Commerce Experience in addition to being recognized as one of Newsweek’s Fastest Growing Online Shops in 2022. Visit the website at  www.azazie.com.

Media Contact:

Azazie
[email protected] 

Source : Azazie and Former Bachelorette, Charity Lawson, Host a Bridal Tea Luncheon

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

FP Markets, a global multi-asset broker announces sponsorship deal with ICC associate member Cricket Brasil to support its Youth Development Programme.

SYDNEY, Dec. 12, 2023 /PRNewswire/ — FP Markets, an Australian forex and CFDs broker, has announced a partnership with Cricket Brasil to support its thriving youth development programme which provides a pathway for children to finish schooling, attend university and build a future around the game. In its initial phase, the sponsorship will focus on supporting 3 specific areas:

FP Markets enhances its Corporate Social Responsibility (CSR) programme with Sponsorship of the Cricket Brasil Youth Development Programme Education – Helping fund the university education of project leaders (known as the "Black T-shirts") through the Cricket Brasil University Scheme providing young Brazilians access to higher education and providing life-changing opportunities as well as teaching them the key core values of Respect, Leadership and Community. Infrastructure Upgrades – Completion of the Cricket Brasil indoor school and high performance center in Poços de Caldas, Minas Gerais. Community Support – Supporting the development of local development officers to help grow the game in the local communities.

Craig Allison, CEO, FP Markets commented "FP Markets recognises that being an industry leader requires more than just being exceptional in the trading industry. It involves actively engaging with communities and contributing in ways that can make a real difference to people’s lives. By Supporting Cricket Brasil we know we are making a real difference to the lives of young Brazilians and leaving a long-lasting positive impact on the local community through the glorious game and values set by cricket"

Matt Featherstone, President Cricket Brasil "Partnerships like this make all the difference. The expansion of Cricket Brasil as a direct result of this partnership will provide more opportunities for young Brazilians to play the great game as well as join our University Scheme which educates more Cricket Development officers who in turn increase local engagement and participation."

Sergio Azevedo, Mayor of Poços de Caldas: "We are very privileged in Poços de Caldas to be known as the home of Cricket Brasil. It is a very unique situation in a country synonymous with football that we have more children in the town playing Cricket than Football!"

Fara Gorsi, ICC Development Manager, Americas: "The new partnership formed between FP Markets, (an Australian organization) and Cricket Brasil is a testament to their unequivocal commitment to the game and positively impacting the lives of thousands of young kids. The partnership with FP Markets will aid in the growth and development of the cricket ecosystem. As the natural trailblazers in the region, Cricket Brasil continue to strive for progress and we are very excited and proud to see Cricket Brasil grow from strength to strength in ICC Americas"

FP Markets sponsorship and donation initiatives aim to empower individuals and organizations striving to improve lives through community engagement, education and innovation, diversity and inclusion, ethical business practices and sustainability and hopes these collaborations can impart lasting effects.

FP Markets is committed to making a positive impact on society and the environment through its Corporate Social Responsibility initiatives. The dedication to CSR is rooted in our values, and we strive to make a difference to current and future generations by supporting projects that actually deliver.

Established in 2005, FP Markets is a Multi-Regulated brand providing clients with over 10,000 tradable instruments across key asset classes and offers aggregate pricing across several top-tier liquidity providers. Additionally, FP Markets deliver Consistently Tight Spreads, Lightning Execution, Unmatched 24/7 Multilingual Customer Support, and various Account Types to suit all trading strategies and styles.

Notes to Editors About FP Markets:

FP Markets is a Multi-Regulated Forex and CFDs Broker with over 18 years of industry experience. The company offers highly competitive interbank Forex spreads starting from 0.0 pips. Traders can choose from the leading powerful online trading platforms, including FP Markets’ Mobile App, MetaTrader 4, MetaTrader 5, WebTrader, cTrader, and Iress. The company’s outstanding 24/7 multilingual customer service has been recognised by Investment Trends and awarded ‘The Highest Overall Client Satisfaction Award’ over five consecutive years. FP Markets has been awarded the ‘Best Global Forex Value Broker’ for five consecutive years (2019, 2020, 2021, 2022, 2023) at the Global Forex Awards. FP Markets has been awarded the ‘Best Forex Broker – Europe’ and the ‘Best Forex Partners Programme – Asia’ at the Global Forex Awards 2022 and 2023. FP Markets has been awarded ‘Best Trade Execution’ at the Ultimate Fintech Awards 2022. FP Markets was crowned ‘Best CFD Broker in Africa’ at FAME Awards 2023. FP Markets Awarded ‘Best Trade Execution’ and ‘Most Transparent Broker’ at the Ultimate Fintech Awards APAC 2023

For more information on FP Markets’ comprehensive range of products and services, visit https://www.fpmarkets.com/.

About Cricket Brasil:

Total Players: 24,565 (2009 – 250) Male 12,491 Female 12,074 Cricket Centre numbers: 3 Cricket centers in place currently (Caldense, Cricket Brasil High Performance Center and Cricket Brasil Indoor Center) Regional Hubs in 4 other states: Development: 1. Poços de Caldas Hub, 2. Botelhos Hub. SP: 3. Aguaí Hub. BA: 4 Santa Luz Hub. DF: Brasília Hub Contracted Players: 14 contracted players on the Women’s National Team. Another 18 players on the Women’s Development Squad and 20 at the Men’s Development Squad. Elite Squad age groups: 94% of players from age 16-24 Coaches (HP & Other) & Qualified Umpires/Scorers. Information submitted to ICC in 2023: Active Coaches: 139 Male 85, Female 54 Active Umpires: 143 Male 94, Female 49 Cricket Brasil is an ICC associate nation. Matt Featherstone – ICC global representative for the associate nations for 4 years and currently on the ICC Governance Committee

For more information on Cricket Brasil, visit https://cricketbrasil.org/en/ Facebook: https://www.facebook.com/brasilcricket

Instagram: cricketbrasil Twitter: @brasil_cricket

FP Markets enhances its Corporate Social Responsibility (CSR) programme with Sponsorship of the Cricket Brasil Youth Development Programme

Source : FP Markets enhances its Corporate Social Responsibility (CSR) programme with Sponsorship of the Cricket Brasil Youth Development Programme

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 12, 2023 /PRNewswire/ — IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, today announced the latest analysis results from the FUMANBA-1 study of Equecabtagene Autoleucel for the treatment of multiple myeloma in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting. The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.

Oral Presentation Overview

Presentation Title: Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Session Date and Time: Monday, December 11, 2023, 11:30 AM (San Diego)

Publication Number: 761

Presenter: Dr. Jue Wang, Associate Professor, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

The presentation is based on a post-hoc analysis of the FUMANBA-1 study. The FUMANBA-1 Study(Registration No.: NCT05066646) is a Phase Ib/II, single-arm, multicenter study to assess the efficacy and safety of the investigational drug Equecabtagene Autoleucel (IASO R&D code: CT103A, Innovent R&D code: IBI326), a fully human CAR-T cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM) who have received 3 or more lines of treatment.

As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients. Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%. Among subjects without prior CAR-T therapy, the ORR reached 98.9%, the sCR/CR rate reached 82.4%, and the 12-month progression-free survival (PFS) rate was 85.5%.

Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative. The median time to achieve MRD negativity was 15 days, with 80.8% of patients remaining MRD negative at 12 months post infusion.

In addition, Equecabtagene Autoleucel could persist in the body for an extended period of time the median duration was 307.5 days. 12 months after infusion, 50% of patients had a vector copy number (VCN) above the lower limit of detection; and 24 months after infusion, VCN could still be detected in 40% of the patients.

Based on the descriptive analysis, patients receiving eque-cel achieved MRD negativity irrespective of cytogenetics status，extramedullary disease status，number of prior lines of therapy，and performance status. It suggests that eque-cel as immune cell therapy showed strong killing effect to myeloma cells without affecting by these factors.

 In the FUMANBA-1 study, 90 RRMM patients without prior CAR-T therapy were evaluable for MRD test at 10-5. The results showed:

(1) An important prognostic factor for progression-free survival (PFS) in patients with RRMM treated with Equecabtagene Autoleucel is sustained MRD negativity: When comparing the PFS of patients in different MRD negative duration groups, those in the ≥ 6 months and ≥ 12 months group were significantly better than those in the < 6 months group. This was particularly true for those in the ≥ 12 months MRD negative duration group.

(2) There is a correlation between the persistence of CAR-T cells and sustainability of MRD negativity after infusion of Equecabtagene Autoleucel: Overall, there is a positive correlation between the two. This was particularly evident in subgroup analysis. The Triple-class exposure subgroup, the previous autologous transplantation treatment history subgroup, the high-risk cytogenetic abnormality subgroup, etc., showed a moderate to strong positive correlation between the persistence of CAR-T cells (VCN persistence) after infusion of Equecabtagene Autoleucel and the duration of MRD negativity. The correlation may become more significant in the future with longer term follow-up data, which could further reveal the positive correlation between long-term survival of CAR-T cells and long-term maintenance of MRD negativity.

"Studies have shown MRD is a biomarker that affects the long-term survival of RRMM patients. It’s necessary to maintain MRD negativity to improve the prognosis of RRMM patients and extend PFS. Equecabtagene Autoleucel has overcome two difficulties faced by traditional therapies in maintaining MRD negativity. First, it has increased the proportion of patients with MRD-negative persistence past 12 months from less than 10% to 80%. Second, only one-time infusion is needed to achieve sustainable MRD negativity. Traditional therapies require continuous medication to maintain MRD negativity, and once medication is stopped, patients face the risk of relapse. Patients who do not stop the medication will be facing the potential risk of inducing drug-resistant clones. Long-term medication and complex therapies increase direct treatment costs, seriously affect patients’ quality of life. The adverse effects caused by long term treatment also increase indirect costs to patients and their families. With its outstanding long-term persistence in the body, Equecabtagene Autoleucel can achieve lasting and deep remission in RRMM patients who have failed multiple lines of treatment. We expect that it will give more patients the hope of a cure," said principal investigators Professor Lu-gui Qiu, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and Professor Chunrui Li, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.

About IASO Bio

IASO Bio is a biopharmaceutical company engaged in the discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. IASO Bio possesses comprehensive capabilities spanning the entire drug development process, from early discovery to clinical development, regulatory approval, and commercial production.

The pipeline in the company includes a diversified portfolio of over 10 novel products, including Equecabtagene Autoleucel (a fully human BCMA CAR-T injection). Equecabtagene Autoleucel received New Drug Application (NDA) approval from China’s National Medical Products Administration (NMPA) and U.S. FDA IND approval for the treatment of RR MM.

Leveraging its strong management team, innovative product pipeline, GMP production, as well as integrated manufactural and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfil unmet medical needs to patients in China as well as around the world. For more information, please visit http://www.iasobio.com or www.linkedin.com/company/iasobiotherapeutics.

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent’s mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients’ lives. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), SULINNO® (Adalimumab Injection), HALPRYZA® (Rituximab Injection), Pemazyre® (Pemigatinib Oral Inhibitor), Olverembatinib, Cyramza® (Ramucirumab Injection), Retsevmo® (Selpercatinib Capsules ), FUCASO® (Equecabtagene  Autoleucel Injection) and SINTBILO® (Tafolecimab Injection).Additionally, we have 2 assets are under NMPA NDA review, 5 assets are in Phase III or pivotal clinical trials, and 19 more molecules in early clinical stage.

Innovent has also entered into more than 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives.

Contact:

IASO Bio
Media: [email protected]
Investors: [email protected] 

Innovent Biologics
Media:
[email protected]
+86 512-6956 6088
Investors:
ir@innoventbio.com
+86 512-6956 6088

Source : IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Deal Will Bring First-Ever 270-Degree Panoramic ScreenX Auditorium to Tōhoku Region, Set To Open December 15 following CineAsia

HOLLYWOOD, Calif., Dec. 12, 2023 /PRNewswire/ — At CineAsia, CJ 4DPLEX, the world’s leading producer of premium film formats and cinema technologies, and Tokyu Recreation Co., Ltd., owner of 109 Cinemas, announced they have expanded their partnership to open five more 270-degree panoramic ScreenX auditoriums theaters across Tokyu Recreation’s 109 Cinemas in Japan, including the first-ever ScreenX in the Tōhoku region set to open on December 15.

From L to R: L to R Don Savant, Chief Business Officer, CJ 4DPLEX Jongryul Kim, CEO, CJ 4DPLEX, Shinzo Kanno, President, Tokyu Recreation, Masanori Kubo, Senior Managing Director, Tokyu Recreation

ScreenX enhances the traditional movie-going experience by extending the screen onto surrounding walls of the auditorium, creating a 270-degree panoramic viewing experience. Through its unique presentation of select scenes and exclusive imagery, ScreenX immerses audiences in an unparalleled visual environment. The new ScreenX auditoriums have fortified CJ 4DPLEX’s partnership with the Japan-based movie theater exhibitor, a joint venture that has already established three ScreenX theaters, and eight 4DX theaters. The first-ever 109 Cinemas ScreenX auditorium opened in Meiwa in March of 2020.

"The demand for premium cinema experiences in Japan continues to grow and we are thrilled to be a part of that market expansion," said Jongryul Kim, CEO of CJ 4DPLEX. Our collaboration with Tokyu Recreation and 109 Cinemas also continues to expand as they lead the industry in providing premium theater options to consumers across Japan."

"Shaping the movie theater experience has perpetually been our objective for many years. Our partnership with CJ 4DPLEX allows for a complete revitalization of how films are enjoyed and now, with the introduction of five new ScreenX auditoriums, 109 Cinemas continues to be a leader in the Japanese cinema sector delivering cutting-edge cinematic style and expansive scenes to our audiences in visually immersive formats," said Shinzo Kanno, President, Tokyu Recreation.

"As our revolutionary 270-degree multi-projection ScreenX technology continues to grow globally, we are looking forward to adding another five locations in Japan," said Don Savant, Chief Business Officer, CJ 4DPLEX, "Tokyu Recreation and 109 Cinemas have been an instrumental part of ScreenX’s success in Asia and for that we are very thankful to have such a strong partner."

The signing ceremony was attended by Shinzo Kanno, President, Tokyu Recreation, Masanori Kubo, Senior Managing Director, Tokyu Recreation, Jongryul Kim, CEO, CJ 4DPLEX, and Don Savant, Chief Business Officer, CJ 4DPLEX.

109 Cinemas will start this extensive roll out of venues including opening the ScreenX theater in Tomiya within the Tōhoku region on December 15 in time for Warner Bros. Pictures’ "Wonka."

About CJ 4DPLEX:
CJ 4DPLEX is a leading, next-generation cinema technology company, headquartered in Seoul with international offices in Los Angeles and Beijing. The company has created innovative film technologies for theaters worldwide that include ‘ScreenX’, ‘4DX’, and ‘4DX Screen’ for consumers to experience films in ways that were never before possible.

CJ 4DPLEX is a part of the CJ Group conglomerate that also includes entertainment powerhouses CJ CGV, the fifth largest theater chain in the world, and CJ ENM (CJ Entertainment & Media), who produced the Academy Award®, Golden Globe® and SAG Awards winning film, "Parasite". CJ 4DPLEX was named Most Innovative Company of 2017 and 2019 in Live Events by Fast Company, and the technology has been recognized with Silver at the Edison Awards in the Media and Visual Communications-Entertainment category in 2015 and 2018.

ScreenX is the world’s first multi-projection cinema with an immersive 270 degree field of view. By expanding the image beyond the frame and onto the walls of the theater, ScreenX places the audience directly at the center of the story, creating a visually immersive viewing experience unlike any other. To date, there are over 366 ScreenX auditoriums around the world in 40 countries.

4DX provides moviegoers with a multi-sensory cinema-going experience, allowing audiences to connect with movies through motion, vibration, water, wind, snow, lightning, scents, and other special effects that enhance the visuals on-screen. Each 4DX auditorium incorporates motion-based seating synchronized with more than 21 different effects and optimized by a team of skilled editors. To date, there are over 791 4DX auditoriums around the world, spanning over 70 countries.

Source : CJ 4DPLEX and Tokyu Recreation Co. Expand Joint Venture With Five Additional ScreenX Auditoriums

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

FREMONT, Calif., Dec. 12, 2023 /PRNewswire/ — Star Charge, a global leader in Electric Vehicle Charging Infrastructure with a proven track record of delivering up to 2 million EV chargers in more than 60 countries, is excited to announce the expansion of its manufacturing facility to the USA with the establishment of a new plant in Columbus, Ohio. The decision to set up in Central Ohio is driven by a favorable business environment, reasonable operational costs, a robust supply chain, and attractive government incentives. The plant is set to commence production in the first quarter of 2024.

Star Charge’s new plant in Columbus, Ohio

This factory will see an initial production capacity of over 20,000 chargers annually, incorporating a range of AC, DC, and bi-directional chargers, spanning from 7kW to 480kW, particularly designed to meet the needs of various applications, including residential, school buses, commercial fleets, and public charging stations. The Ohio plant will manufacture NEVI (Next-Generation Electric Vehicle Infrastructure) ready DC fast chargers, including the Titan 150KW and Neptune split system models. Renowned for their over 97% efficiency and intelligent dynamic load management features, these chargers contribute to the operational efficiency of charging stations.

Herman Chang , CEO of Star Charge stated, "The US is one of the largest EV markets and is expected to continuously grow over the next decade. Establishing our new facility in Ohio aligns with our commitment and is crucial to our company strategy". He further explained, "Alongside this new plant, we are actively seeking to engage with local talents, foster strategic partnerships, and establish dedicated service teams to enhance our operations and accessibility to our US customers. Our goal is to work with our US customers to explore innovative solutions that drive e-mobility adoption and microgrids for a sustainable future".

Join us at CES 2024:

Star Charge invites you to visit Booth 8905 at the Las Vegas Convention Center North Hall during CES 2024 from Jan. 9 ~ 12. Explore our latest innovations in EV charging infrastructure and microgrid solutions for various scenarios including residential, public charging, commercial & industrial. On-site events will be scheduled at the booth and Star Charge executives will be present to discuss the growth plans in the US market.

About Star Charge:

Star Charge, a global leader in electric vehicle charging infrastructure and microgrid solutions, operates in 20 countries with manufacturing facilities in China, Vietnam, and the USA. To contribute to the energy transition towards a more sustainable future, we focus on evolving our solutions through innovative technology in the e-mobility sector, aiming to build a mobile and efficient energy network.

For additional details, please visit www.starcharge.com

Source : Star Charge Expands its Manufacturing to USA in Central Ohio to Meet Increasing Needs

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ClinicalTrials.gov ID: NCT06090331) for TLX250-CDx (89Zr-DFO-girentuximab). TLX250-CDx is the Company’s first-in-class, non-invasive investigational positron emission tomography (PET) imaging agent in clear cell renal cell carcinoma (ccRCC).

The patient was dosed at ARA Diagnostic Imaging at Austin Radiological Association in Austin (TX, U.S.) following U.S. Food and Drug Administration (FDA) agreement to proceed.

FDA agreement for an EAP follows the completion of Telix’s successful global Phase III ZIRCON study (Zirconium in Renal Cancer Oncology, ClinicalTrials.gov ID: NCT03849118), which reported positive results in November 2022, meeting all co-primary and secondary endpoints.[1]

Dr John Leahy, molecular radiologist and nuclear medicine specialist at ARA Diagnostic Imaging and a Principal Investigator on the EAP stated, "With TLX250-CDx, for the first time, urologists and urologic oncologists may have a non-invasive way to determine the presence of ccRCC, the most common and aggressive form of kidney cancer. We are therefore extremely pleased to have been selected as the inaugural site for this national EAP, with patients in Austin and the surrounding area now able to benefit from greater confidence in their kidney cancer diagnosis and treatment planning."

Mary Jessel, Senior Vice President of Global Medical Affairs at Telix added: "Ahead of regulatory approval, this EAP provides continued access to TLX250-CDx to address a clear unmet patient need. ZIRCON results demonstrate that TLX250-CDx has potential to become a new standard of care in the diagnosis and staging of ccRCC, where existing imaging can be inconclusive."

Under its EAPs – sometimes called ‘compassionate use’ – the FDA works with companies to allow access to investigational products outside of a clinical trial to patients for whom there are no comparable or satisfactory alternate options.

Telix is progressing towards a Biologics License Application (BLA) submission for TLX250-CDx with the FDA and other equivalent applications with regulatory agencies in key commercial jurisdictions.

U.S. patients, or physicians who may have eligible patients in the U.S., can e-mail [email protected] for further information about the TLX250-CDx EAP.

Telix’s Policy on Offering Compassionate Use to Investigational Medicines can be downloaded at the following link.

For more information about ongoing clinical trials of TLX250-CDx, please visit https://telixpharma.com/our-portfolio/clinical-trials/

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn.

TLX250-CDx has not received a marketing authorisation in any jurisdiction. Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA),[2] by the Australian Therapeutic Goods Administration (TGA),[3] and by Health Canada.[4]

Telix’s SENSEI® ultra-miniaturised robotic gamma probe is registered as a Class 1 device with the FDA, and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area for intra-operative detection of sentinel lymph nodes.[5]

Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: [email protected]

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments.  Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.

©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

[1] Telix ASX disclosure 7 November 2022.

[2] Telix ASX disclosure 20 December 2021.

[3] Telix ASX disclosure 2 November 2021.

[4] Telix ASX disclosure 14 October 2022.

[5] Lightpoint Medical media release 20 January 2021.

Source : First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHANGHAI, Dec. 11, 2023 /PRNewswire/ — Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Trial of 9MW2821 versus Investigator’s Choice of Chemotherapy for Treating Unresectable Locally Advanced or Metastatic Urothelial Carcinoma in Patients Previously Treated with Platinum-Containing Chemotherapy and PD-(L)1 Inhibitors" has been approved. The company will now officially initiate the Phase III clinical study of 9MW2821 for treating locally advanced or metastatic urothelial carcinoma in patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

9MW2821 is a novel Nectin-4 targeting ADC developed independently by Mabwell, marking the first of its kind among the products developed in China with the same target to enter clinical trials. As of December 5, 2023, more than 250 subjects were enrolled. In the Phase II clinical trial of 9MW2821, at a dose of 1.25 mg/kg, the monotherapy resulted in an objective response rate (ORR) of 62.2% (95% CI: 44.8%–77.5%) and a disease control rate (DCR) of 91.9% (95% CI: 78.1%–98.3%) in patients with advanced urothelial carcinoma. The median progression-free survival (PFS) was 6.7 months (95% CI: 3.8–NR), while the median overall survival (OS) has not been reached yet.

Currently, multiple clinical trials are being conducted simultaneously for this project. Clinical trials on combination therapy with other treatments, in addition to monotherapy, are also advancing. Promising antitumor activity coupled with favorable safety profiles has been observed across various cancer types.

About Urothelial Carcinoma
According to the American Society of Clinical Oncology, bladder cancer is the ninth most common malignant tumor in terms of incidence and ranks thirteenth in mortality among malignant tumors. According to the 2016 Chinese national cancer statistics published by the National Cancer Center in February 2022, there were 82,300 new bladder cancer cases, with an incidence of 3.53 per 100,000 individuals. Urothelial carcinoma, ranking among the top ten most prevalent cancers in China, is characterized by its tendency toward metastasis and recurrence. Advanced urothelial carcinoma is associated with short survival, contributing to a substantial disease burden in China and seriously compromising patients’ survival and quality of life.

About 9MW2821
9MW2821 is a novel Nectin-4 targeting ADC developed by world-class ADC development platform and automated high-throughput antibody discovery platform of Mabwell. It achieves site-specific modification of antibody through proprietary conjugate technology linkers and optimized ADC conjugation process. 9MW2821 can specifically bind to Nectin-4 on the cell membrane surface, be internalized and release cytotoxic drug, and induce the apoptosis of tumor cells. The company is conducting several clinical trials on a range of indications, including urothelial carcinoma and cervical cancer. Currently, the R&D progress of 9MW2821 ranks first in China and second in the world. 9MW2821 is the first to read out preliminary clinical data in cervical cancer among the products with the same target in the world.

About Mabwell
Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 14 pipeline products in different R&D stages based on a world-class and state-of-the-art R&D engine, including 10 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, auto-immune diseases, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Of these, 2 products have been approved and commercialized, 1 product has been filed for MA approval, 1 product is in the preparation of filing, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and several provincial and municipal science and technological innovation projects. Mabwell’s Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base located in Shanghai is under construction. Our mission is "Explore Life, Benefit Health" and our vision is "Innovation, from ideas to reality". For more information, please visit www.mabwell.com/en.

Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

Source : Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network